Discovery toxicology assays
Understanding and managing toxicity at the earliest possible is important to improve safety and efficacy of therapeutic molecules in drug development. At BioMedha, we have developed robust tools for implementing and assessing toxicity risk at an early stage.
Mitochondrial toxicity
Figure-A: Compound dose response curve (4hrs treatment) against Glu/Gal ATP and Mitochondrial Membrane Potential (MMP) assays.
Cardiotoxicity
Figure-B: IC50 curves for hERG channel blockers in Predictor™ FP assay.
Liver toxicity
Figure-C: EC50 curves against HepG2.
AchE inhibition
Figure-D: Donepezil dose dependent AchE inhibition in human whole blood.
Immunogenicity
Figure-E: Concentration of each Cytokine analyte (pg/mL) in PBMC supernatant from eight-donors. Data points within each donor were represented with one colour code.
DNA damage
Figure-F: Doxorubicin induced DNA damage response in A549 cells using double-stranded break marker phospho-H2AX. Fluorescently stained nuclei (Blue Hoechst stain) and nuclei positive for the DNA damage marker (Pink/ Red/orange).
Identifying potential toxic compounds as early as possible in the drug discovery is crucial. At BioMedha, we have established robust In vitro assays to assess drug-induced toxicity. Partner with us to accelerate your drug discovery portfolio.